Cue Biopharma, Inc. 8-K

What Happened
Cue Biopharma, Inc. announced its financial results for the quarter and year ended December 31, 2025 via a press release dated March 16, 2026. The company filed a Current Report on Form 8-K (Accession No. 0001193125-26-108292) to furnish that press release as Exhibit 99.1. The filing was signed by Usman Azam, President and Chief Executive Officer. The company states the furnished information is not “filed” under Section 18 of the Exchange Act and is not incorporated by reference in other filings except where expressly stated.

Key Details

• Filing date: March 16, 2026; press release furnished as Exhibit 99.1.
• Reporting period covered: quarter and year ended December 31, 2025 (Q4 and full-year 2025).
• Signed by: Usman Azam, President & CEO.
• Legal note: Information furnished on this Form 8-K is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters
This 8-K signals that Cue has publicly released its latest earnings and operational results—key information investors use to evaluate recent revenue, earnings, and quarterly performance trends. Because the filing only furnishes the press release (and is not “filed” under Section 18), investors should review the press release (Exhibit 99.1) for the specific financial figures and monitor any follow-up filings (e.g., 10-Q/10-K) or investor calls for audited details and management commentary.